Alkermes (ALKS) Following Favorable Alixorexton Data Is The Orexin Story Already Priced In
Alkermes (ALKS) stock is drawing fresh attention after the company reported favorable phase 2 Vibrance-1 data for its orexin 2 receptor agonist alixorexton in narcolepsy type 1, alongside ongoing phase 3 Brilliance studies.
The latest Vibrance-1 data arrives after a strong run for Alkermes, with the share price up 63.1% year to date and the 1-year total shareholder return at 54.0%, despite a recent pullback that includes a 7.1% 1-month share price decline.
Scan beyond Alkermes and compare other potential breakout biopharma and healthcare stocks with strong fundamentals using our hand picked list of solid balance sheet and fundamentals (52 results)
After a strong run for Alkermes and a recent pullback, the stock now sits at a sizeable discount to both intrinsic estimates and analyst targets. Is that a valuation gap, or a clear signal that the market wants more proof?
Most Popular Narrative: 17.7% Undervalued
The most followed Alkermes narrative sees fair value at $56, compared with a last close of $46.10, and ties that gap tightly to orexin progress and margin assumptions.
Results from the Vibrance 1 Phase II study and the expanding orexin agonist pipeline de-risk the company's long-term R&D strategy, opening avenues to additional addressable disorders beyond narcolepsy and highlighting potential for future multi-indication revenue streams pending successful late-stage trials and commercialization.
Read the complete narrative. Read the complete narrative.
Want to understand why this Alkermes fair value sits well above the current price? The narrative leans on sustained revenue expansion, a sharp profitability shift and a future earnings multiple that assumes meaningful orexin traction beyond the initial indications.
Result: Fair Value of $56 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Alkermes still faces real execution risk if orexin trials disappoint or timelines slip, and rising R&D spending could pressure margins if outcomes fall short.
Find out about the key risks to this Alkermes narrative.
Another View On Alkermes Valuation
The popular Alkermes narrative leans on future earnings to argue the stock is undervalued. Yet on a simple P/E basis the picture looks far less comfortable. Alkermes trades on about 117x earnings, compared with 17x for the wider US biotechs industry and 93.6x for peers, while the fair ratio sits at 40.4x.
That gap leaves less room for disappointment if earnings or orexin execution fall short, even if some investors see it as the price of growth. Which matters more for you: the upside in long range forecasts, or the current multiple you are paying?
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
With Alkermes attracting both optimism and concern, it makes sense to look under the hood yourself. You can move quickly to shape your own view with the full picture of 2 key rewards and 3 important warning signs
Looking for more investment ideas beyond Alkermes?
If you are serious about making stronger decisions after looking at Alkermes, do not stop here. The Simply Wall St screener surfaces other stocks with clear, data backed stories.
- Target resilient balance sheets and steady fundamentals by reviewing our hand picked list of solid balance sheet and fundamentals (52 results) that many investors overlook.
- Hunt for potential mispricing by scanning a curated set of 47 high quality undervalued stocks that align with solid underlying metrics.
- Prioritize stability and income by focusing on 82 resilient stocks with low risk scores before the rest of the market catches on.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com